YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback